Sab Biotherapeutics Stock Today
| SABS Stock | USD 2.08 0.02 0.95% |
PerformanceSoft
| Odds Of DistressRisky
|
SAB Biotherapeutics is selling for under 2.08 as of the 31st of August 2025; that is 0.95 percent decrease since the beginning of the trading day. The stock's lowest day price was 2.03. SAB Biotherapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 2nd of June 2025 and ending today, the 31st of August 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of February 2021 | Category Healthcare | Classification Health Care |
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company was founded in 2014 and is based in Sioux Falls, South Dakota. Sab Biotherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 9.29 M outstanding shares of which 501.96 K shares are at this time shorted by private and institutional investors with about 0.14 trading days to cover. More on SAB Biotherapeutics
Moving against SAB Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
SAB Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Executive Chairman | Samuel Reich | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsSAB Biotherapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand SAB Biotherapeutics' financial leverage. It provides some insight into what part of SAB Biotherapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
SAB Biotherapeutics (SABS) is traded on NASDAQ Exchange in USA. It is located in 777 W 41st St., Miami Beach, FL, United States, 33140 and employs 63 people. SAB Biotherapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.66 M. SAB Biotherapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.29 M outstanding shares of which 501.96 K shares are at this time shorted by private and institutional investors with about 0.14 trading days to cover.
SAB Biotherapeutics currently holds about 16.62 M in cash with (34.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39.
Check SAB Biotherapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of SAB Biotherapeutics is $21.66 Million. SAB Biotherapeutics owns 18.76 % of its outstanding shares held by insiders and 18.66 % owned by institutions. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check SAB Ownership Details
SAB Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2025-03-31 | 11.4 K | |
| Renaissance Technologies Corp | 2025-03-31 | 10 K | |
| Advisor Group Holdings, Inc. | 2025-03-31 | 4.9 K | |
| Sachetta Llc | 2025-06-30 | 4.1 K | |
| Tower Research Capital Llc | 2025-06-30 | 726 | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 449 | |
| Mccormack Advisors International | 2025-03-31 | 217 | |
| Gs Investment Inc | 2025-06-30 | 200 | |
| Jpmorgan Chase & Co | 2025-03-31 | 103 | |
| Bvf Inc | 2025-06-30 | 917.8 K | |
| Sessa Capital Im Lp | 2025-03-31 | 458.5 K |
SAB Biotherapeutics Historical Income Statement
SAB Stock Against Markets
SAB Biotherapeutics Corporate Management
| MBA CMA | Ex CFO | Profile | |
| Eddie Sullivan | President, CoFounder | Profile | |
| MD MBA | Executive Officer | Profile | |
| Hua Wu | Senior Development | Profile | |
| Mark Conley | Interim Officer | Profile | |
| Catherine DeRose | Vice Resources | Profile |
Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.